Context Therapeutics (NASDAQ:CNTX) Coverage Initiated at Jones Trading

Jones Trading assumed coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a report released on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $7.00 price target on the stock.

Other research analysts have also issued reports about the company. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Thursday, November 6th. Guggenheim assumed coverage on Context Therapeutics in a research report on Thursday, September 18th. They issued a “buy” rating and a $5.00 price target on the stock. Wall Street Zen raised Context Therapeutics to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright lifted their price target on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.67.

Context Therapeutics Stock Down 7.5%

Shares of CNTX opened at $1.11 on Monday. The company has a market cap of $101.99 million, a P/E ratio of -4.63 and a beta of 1.94. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $1.55. The firm’s 50 day moving average price is $1.15 and its 200 day moving average price is $0.94.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Research analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Trading of Context Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC grew its stake in shares of Context Therapeutics by 60.5% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after purchasing an additional 35,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the period. Finally, Citadel Advisors LLC purchased a new position in Context Therapeutics in the 3rd quarter valued at $100,000. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.